Interestingly, gene expression programs driven by oncogenic KMT2A-fusions are also relevant for other subtypes of leukemia, especially NPM1-mutant (NPM1c) AML [6, 8]. The gene discussed is NPM1; the disease is acute myeloid leukemia.